Jump to content
In this section we have spot diagnoses posted on a daily basis since June 2010, now over 1700! You can review the archived cases and read the suggested diagnoses by users and the final comment by Dr Uma Sundram, the Editor-in-Chief and main spot diagnosis host. Case are uploaded each week day by 10 a.m. UK time with the correct diagnosis will generally be posted at 8 p.m. UK time. Why not view the most recent spot diagnosis and proffer a diagnosis?

Case Number : Case 2450 - 22 November 2019 Posted By: Dr. Richard Carr

Please read the clinical history and view the images by clicking on them before you proffer your diagnosis.
Submitted Date :
   (0 reviews)

M72. 6/52 purplish plaques. ?Lymphoma. Scalp bx.


  • Like 1
  Report Record

User Feedback


Krishnakumar subramanian

Posted

pan dermal dense lymphoid infiltrate both perivascular and perifollicular

green zone is there

CD 3 few cells positive, sir can we have CD20

 

Share this comment


Link to comment
share_externally

Saleem Taibjee

Posted

Mmmm... CD123? CD56? or please widen the T-cell and B-cell panel, in case this is loss of antigen expression.

Share this comment


Link to comment
share_externally

Agree with Dr Salem. I’ve seen a similar case recently. Cd4+ cd56+ cd123+. Blasting dendritic plasmocytoid Lymphoma.  Is the patient treated for myeloid leukemia?

Share this comment


Link to comment
share_externally

Krishnakumar subramanian

Posted

CD56 and Cd 123 staus, Blood smear and MPO stain

Share this comment


Link to comment
share_externally

Krishnakumar subramanian

Posted

sir the battery of round cell tumors comes into differential diagnosis. How common is double negative lymphomas in the skin

Share this comment


Link to comment
share_externally

Dr. Mona Abdel-Halim

Posted

Will check CD5,CD7 and CD79a before going to a full work up of leukemic deposits including work up for BPDCN. The duration is only 6 weeks and this will be more with a leukemic deposit or secondaries of nodal disease.  

Share this comment


Link to comment
share_externally

Dr. Richard Carr

Posted

This is a BPDCN (CD4+, CD56+) recurrence. Remarkably about 18 months down the line from chemotherapy treatment. You should be aware there are now some promising treatments e.g. anti-CD123 (FDA approved)

MD Anderson: Dr Naveen Pemmaraju (Lead Clinician)
On BPDCN cells there’s a marker called CD123. Tagraxofusp, a targeted therapy we’ve helped develop and study, attaches to that marker and then kills the cancer cells. The results are very encouraging. Over 90% of patients who received tagraxofusp as their first treatment had a major response. That means that the skin lesions and/or bone marrow lesions disappeared. A paper we recently published in the New England Journal of Medicine shows that we’re more than two years into our study, and we still haven’t reached the median length of survival for these patients. So we’ve apparently at least doubled the survival time when comparing to this historic expectation for our patients. The U.S. Food and Drug Administration approved tagraxofusp for treatment of BPDCN in December 2018; it’s now considered one of the standard treatments for this disease.

https://www.nejm.org/doi/full/10.1056/NEJMoa1815105

Share this comment


Link to comment
share_externally



Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...

×
×
  • Create New...